Profound Medical Corp. (NASDAQ:PROF) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a significant revenue increase, improved margins, and strategic product launches, suggesting strong growth potential. Despite some regulatory and competitive risks, the introduction of new products and market expansion plans are promising. The Q&A section shows confidence in growth, albeit with some vagueness on specifics. Overall, the positive financial performance and future growth expectations outweigh the uncertainties, indicating a positive stock movement.
Key Financial Performance
Revenue $4.2 million, an increase of 108% from $2 million in Q4 2023.
Gross Margin 71%, compared to 52% in Q4 2023.
Total Operating Expenses $11.3 million, compared to $9.8 million in Q4 2023.
Net Loss $4.9 million or $0.20 per share, a 45% improvement from a net loss of $8.9 million or $0.42 per share in Q4 2023.
Cash Position $54.9 million as of December 31, 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Introduction: Introduction of the BPH TULSA AI module, expected to triple the total opportunity for TULSA from 200,000 cancer patients to 600,000 prostate disease patients per year. Launch of TULSA Plus, a combined solution of TULSA-PRO and Siemens interventional MRI, planned for the second half of 2025.
Market Expansion: Targeting the top 50 cancer centers and regional hospitals for TULSA-PRO adoption. Entering B2B markets with established portfolios of ambulatory surgical centers.
Operational Efficiency: Transitioned from a placement model to a capital model in sales. Achieved record revenue of $4.2 million in Q4 2024, a 108% increase from Q4 2023.
Strategic Shift: Complete turnaround of the commercial organization on a global scale, focusing on building a world-class sales and marketing team. Increased patient education programs to build awareness of TULSA procedure.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-Looking Statements: The company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those implied.
Regulatory Issues: The company is subject to regulatory scrutiny, particularly regarding the efficacy of its technology in treating prostate cancer and other conditions.
Competitive Pressures: Profound Medical faces competition from other ablative prostate technologies that are better suited for single unifocal tumors, which may limit its market share.
Market Adoption: The success of TULSA technology depends on its adoption by healthcare providers, which may be influenced by clinical outcomes and reimbursement rates.
Economic Factors: The company anticipates growth but acknowledges potential economic downturns or 'black swan' events that could impact financial performance.
Supply Chain Challenges: The company may face challenges in the supply chain that could affect the availability of its products and overall operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
TULSA AI Module Introduction: Profound plans to introduce the BPH TULSA AI module, which will allow for customized treatment comparable in speed to other modalities, targeting a market of approximately 400,000 patients per year.
TULSA Plus Initiative: The introduction of TULSA Plus, which combines TULSA-PRO and Siemens interventional MRI, is planned for the second half of 2025, streamlining workflow in surgical settings.
CAPTAIN Trial: The CAPTAIN trial is on track, with perioperative data expected to be available at the AUA Annual Meeting in April 2025, which will support acceptance and reimbursement efforts.
2025 Revenue Growth: Profound anticipates high double-digit growth in 2025, with expectations of reaching triple-digit revenue growth in 2026 and beyond.
2024 Revenue Performance: In 2024, Profound achieved a revenue of $4.2 million, a 108% increase from 2023, and aims to build on this foundation for future growth.
Gross Margin Expectations: The company reported a gross margin of 71% in Q4 2024 and expects margins to vary quarter-to-quarter due to product mix.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What gives you confidence in robust growth acceleration in the post-Medicare reimbursement environment?
A:We do not get much pushback on the clinical value of our product, and we have clear models showing profitability for hospitals. Our sales team is energized, and we have a good pipeline.
Q:Can you provide an update on reaching 75 sites by the end of 2025?
A:We will not reach the 75 target this year, but we have grown nicely. We switched to a capital plus recurring model, and we will provide specific numbers later.
Q:What is the updated timing on the launch of the BPH product and any associated regulatory clearances?
A:We are on track for a mid-year launch, but I cannot comment specifically on regulatory clearances.
Q:Have you seen an uptick in actual payments through Medicare in your first quarter?
A:Medicare payments take a long time, so I don’t have good data on actual payments, but we are hearing satisfied users.
Q:Are you pursuing specific insurance companies for reimbursement?
A:Yes, we are adding a team to develop a strategy for which insurance companies to target first.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers on the install base and regulatory clearances for the BPH product launch.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI module
Boost AI
CAPTAN
Dr Profound
Las Vegas
MRI precision
NOVADAQ
PRO
Precision
President
Sales
Stryker
Thermal Boost
apple
ax
capital sale
category
chessboard
degree
director
edge prostate
entity
gland
millimeter
parallel
pixel
precision flexibility
pressure tissue
privilege Arun
sale executive
tissue boiling
tissue destruction
today program
world class
PROF Transcript
Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.
Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Positive8-14
The earnings call highlights strong financial performance with improved gross margins and revenue growth. The CAPTAIN trial data and positive feedback from physicians enhance confidence in TULSA's efficacy. Although there are increased operating expenses and net losses, management's optimistic guidance, strategic partnerships, and successful marketing initiatives signal potential for growth. The Q&A session confirms positive sentiment, with plans for reduced cash burn and strategic expansions. The absence of negative guidance, coupled with favorable reimbursement scenarios, supports a positive outlook for the stock price over the next two weeks.
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Unknown5-9
The earnings call presents a mixed picture: strong revenue growth and promising product development (TULSA AI and CAPTAIN trial) are offset by increased net losses and operating expenses. The Q&A section reveals positive feedback on CAPTAIN data and insurer engagement, but management's vague responses on deal closures and financial guidance introduce uncertainty. The lack of shareholder return initiatives further tempers optimism. Despite potential for future growth, current financial instability and competitive pressures suggest a neutral stock price movement in the short term.
Profound Medical Corp. (NASDAQ:PROF) Q4 2024 Earnings Call Transcript
Positive3-10
The earnings call reveals a significant revenue increase, improved margins, and strategic product launches, suggesting strong growth potential. Despite some regulatory and competitive risks, the introduction of new products and market expansion plans are promising. The Q&A section shows confidence in growth, albeit with some vagueness on specifics. Overall, the positive financial performance and future growth expectations outweigh the uncertainties, indicating a positive stock movement.
PROF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
